Two Rudy Giuliani docs in the works Two feature documentaries focusing on the life and career of former New York mayor and Donald Trump advisor Rudy Giuliani are on the way.
MRC Non-Fiction and Rolling Stone Films are . May 10, 2021
Two feature documentaries focusing on the life and career of former New York mayor and Donald Trump advisor Rudy Giuliani are on the way.
MRC Non-Fiction and Rolling Stone Films are in production on a feature doc based on the 2020
Rolling Stone article “What Happened to America’s Mayor?” by Seth Hettena. It will be directed by Oscar-nominated Zach Heinzerling (
Cutie & The Boxer) and two-time Emmy winner Gabrielle Schonder (
Posted May 10, 2021 9:45 am AMES, Iowa – New variants of the SARS-CoV-2 virus most likely will necessitate the development of more vaccine options in the years ahead, and a biomedical scientist at Iowa State University believes the “key” to that development lies in the way the virus binds to human cells. Michael Cho, a professor of biomedical sciences at Iowa State, is studying how to develop COVID-19 vaccines that target SARS-CoV-2’s receptor-binding domain, or the part of the virus that docks with the host cellular receptor, angiotensin converting enzyme 2 (ACE2). This docking process allows the virus access to the host’s cells, which leads to infection.
Credit: Iowa State University News Service
AMES, Iowa - New variants of the SARS-CoV-2 virus most likely will necessitate the development of more vaccine options in the years ahead, and a biomedical scientist at Iowa State University believes the key to that development lies in the way the virus binds to human cells.
Michael Cho, a professor of biomedical sciences at Iowa State, is studying how to develop COVID-19 vaccines that target SARS-CoV-2 s receptor-binding domain, or the part of the virus that docks with the host cellular receptor, angiotensin converting enzyme 2 (ACE2). This docking process allows the virus access to the host s cells, which leads to infection.
Read Time:
New variants of the SARS-CoV-2 virus most likely will necessitate the development of more vaccine options in the years ahead, and a biomedical scientist at Iowa State University believes the âkeyâ to that development lies in the way the virus binds to human cells.
Michael Cho, a professor of biomedical sciences at Iowa State, is studying how to develop COVID-19 vaccines that target SARS-CoV-2âs receptor-binding domain, or the part of the virus that docks with the host cellular receptor, angiotensin converting enzyme 2 (ACE2). This docking process allows the virus access to the hostâs cells, which leads to infection.
The chair of the Bioengineering Department at The University of Texas at Arlington is investigating whether a combination of nanoparticles and light therapy can better treat traumatic brain injuries on the battlefield.